| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
4,150,000 |
| Market
Cap: |
537.01(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1294 - $1.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aptevo Therapeutics is a clinical-stage, research and development biotechnology company focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. Co.'s lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using Co.'s ADAPTIR™ modular protein technology platform. Co.'s preclinical candidate APVO442 was developed using its ADAPTIR-FLEX™ modular protein technology platform. The ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of improving the human immune system against cancer cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  El-Hibri Fuad |
Board of Directors |
– • • |
2019-07-22 |
4 |
B |
$0.89 |
$26,601 |
D/D |
30,000 |
959,521 |
0.01 |
- |
|
| El-Hibri Fuad |
Board of Directors |
– • • |
2019-07-19 |
4 |
B |
$0.90 |
$23,740 |
D/D |
26,460 |
929,521 |
0.01 |
- |
|
| El-Hibri Fuad |
Board of Directors |
– • • |
2019-07-18 |
4 |
B |
$0.87 |
$12,596 |
D/D |
14,404 |
903,061 |
0.01 |
- |
|
| El-Hibri Fuad |
Board of Directors |
– • • |
2019-07-17 |
4 |
B |
$0.87 |
$16,704 |
D/D |
19,136 |
888,657 |
0.01 |
- |
|
| El-Hibri Fuad |
Board of Directors |
– • • |
2019-07-16 |
4 |
B |
$0.85 |
$9,662 |
D/D |
11,375 |
869,521 |
0.01 |
- |
|
| El-Hibri Fuad |
Board of Directors |
– • • |
2019-07-11 |
4 |
B |
$0.85 |
$12,454 |
D/D |
14,691 |
858,146 |
0.01 |
- |
|
| El-Hibri Fuad |
Director |
– • – |
2019-07-10 |
4 |
B |
$0.85 |
$16,058 |
D/D |
18,919 |
843,455 |
2.39 |
- |
|
| Abdun-Nabi Daniel |
Board of Directors |
– • – |
2019-06-25 |
4 |
B |
$0.90 |
$15,000 |
D/D |
16,667 |
109,351 |
0.01 |
- |
|
| Niederhuber John |
Director |
– • – |
2019-06-14 |
4 |
B |
$0.91 |
$650 |
D/D |
714 |
1,516 |
2.31 |
- |
|
| White Marvin L |
President and CEO |
• • – |
2019-06-14 |
4 |
B |
$0.88 |
$44,000 |
D/D |
50,000 |
293,603 |
0.01 |
- |
|
| Kunz Barbara Lopez |
Board of Directors |
– • – |
2019-06-10 |
4 |
B |
$0.85 |
$8,481 |
D/D |
10,000 |
10,000 |
0.01 |
- |
|
| Harsanyi Zsolt |
Board of Directors |
– • – |
2019-06-07 |
4 |
B |
$0.78 |
$39,000 |
D/D |
50,000 |
50,000 |
0.01 |
- |
|
| Maddux Randy Joe |
Senior VP, Operations |
• – – |
2019-05-31 |
4 |
B |
$0.73 |
$14,600 |
D/D |
20,000 |
50,000 |
0.01 |
- |
|
| Grant Grady Iii |
Board of Directors |
– • – |
2019-05-21 |
4 |
B |
$0.80 |
$7,970 |
D/D |
10,000 |
10,000 |
0.01 |
- |
|
| White Marvin L |
President and CEO |
• • – |
2019-05-20 |
4 |
B |
$0.81 |
$24,300 |
D/D |
30,000 |
243,603 |
0.01 |
- |
|
| White Marvin L |
President and CEO |
• • – |
2019-05-14 |
4 |
B |
$0.78 |
$7,800 |
D/D |
10,000 |
213,603 |
2.81 |
- |
|
| Gross Jane A |
See Remarks |
• – – |
2019-03-01 |
4 |
D |
$1.57 |
$4,255 |
D/D |
(2,710) |
109,583 |
|
- |
|
| Gross Jane A |
See Remarks |
• – – |
2019-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,138 |
112,293 |
|
- |
|
| Adelman Michael |
SVP, Commercial Operations |
• – – |
2019-03-01 |
4 |
D |
$1.57 |
$3,760 |
D/D |
(2,395) |
70,426 |
|
- |
|
| Adelman Michael |
SVP, Commercial Operations |
• – – |
2019-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,318 |
72,821 |
|
- |
|
| Lamothe Jeffrey G. |
SVP and CFO |
• – – |
2019-03-01 |
4 |
D |
$1.57 |
$3,407 |
D/D |
(2,170) |
75,024 |
|
- |
|
| Lamothe Jeffrey G. |
SVP and CFO |
• – – |
2019-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,318 |
77,194 |
|
- |
|
| Stromatt Scott C |
Chief Medical Officer and SVP |
• – – |
2019-03-01 |
4 |
D |
$1.57 |
$7,572 |
D/D |
(4,823) |
216,183 |
|
- |
|
| Stromatt Scott C |
Chief Medical Officer and SVP |
• – – |
2019-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,269 |
221,006 |
|
- |
|
| Mitchell Shawnte |
SVP, GC and Corporate Affairs |
• – – |
2019-03-01 |
4 |
D |
$1.57 |
$3,159 |
D/D |
(2,012) |
80,527 |
|
- |
|
128 Records found
|
|
Page 3 of 6 |
|
|
